AlloVir, Inc. Faces Multiple Class Action Lawsuits Over Securities Fraud Allegations

Investors allege the company made false statements regarding its posoleucel Phase 3 studies, leading to significant losses.

• Multiple law firms have announced class action lawsuits against AlloVir, Inc. for alleged securities fraud.
• The lawsuits claim AlloVir made misleading statements about the efficacy of its posoleucel Phase 3 studies.
• Investors who purchased AlloVir securities between March 22, 2022, and December 21, 2023, are encouraged to join the lawsuits.
• The legal actions allege that AlloVir's public statements were materially false and misleading.
• Investors have until March 19, 2024, to request the court appoint them as lead plaintiff.

3 Articles

Benzinga Benzinga Benzinga